ORLANDO, FL, USA (UroToday.com) - Men with advanced prostate cancer are being treated with androgen deprivation therapy (ADT) for longer periods of time. The use of ADT can be limited by estrogen-deficiency side effects, including a loss of bone and a higher incidence of fractures. C-terminal telopeptides correlate with an increased risk for skeletal morbidity and death in patients with bone metastases. Normalization of bone turnover markers in response to therapy improves long-term outcomes.
Denosumab 60 mg SC q6 months has been FDA approved to decrease the risk of osteoporotic fractures for men on ADT. Estrogenic compounds have been demonstrated to enhance bone health. GTx-758 is an ERα agonist that lowers serum free testosterone greater than an LHRH agonist.
Herein we compare the effects of GTx-758 and leuprolide on markers of bone turnover, C-terminal telopeptides and bone-specific alkaline phosphatase, in men with advanced prostate cancer treated with ADT.....Click here to enlarge and view the poster.
(Click thumbnail to enlarge poster)
Presented by Evan Y. Yu,1 Marc Gittelman,2 Thomas E. Keane,3 Ronald Tutrone,4 Laurence Belkoff,5 Robert Given,6Joel Bass,7 Franklin Chu,8 Mike Gambla,9 Franklin Gaylis,10 James Bailen,11 Robert H. Getzenberg,12 Christopher Coss,12 Michael L. Hancock,12 James T. Dalton,12 and Mitchell S. Steiner12 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
1Univ of Washington, Seattle, WA USA; 2South FL Medical Research, Aventura, FL USA; 3MUSC, Charleston, SC USA 4Chesapeake Urology, Towson, MD USA; Research Associates 5UCSEPA, Bala Cynwyd, PA USA; 6Urology of VA, PLLC, Virginia Beach, VA USA 7AMP of NY – Urology, Syracuse, NY USA; 8San Bernardino Urological Assoc., San Bernardino, CA USA; 9Central Urology Group, Columbus, OH USA 10Genesis Healthcare Partners, San Diego, CA USA; 11First Urology, PSC, Jeffersonville, IN USA; 12GTx, Inc., Memphis, TN USA
View Full 2013 GU Cancers Symposium Coverage